Sean Smith of Eden Research: Funds raised will accelerate our commercial growth
Sean Smith CEO of discusses how the recently raised funds will help accelerate their commercial growth. Recently Eden announced a fundraising totalling £9.9 million before expenses. Sean commented that the fundraise not only provides them with additional capital to commercialise further existing products and fund new areas of the business, but it also serves to strengthen their balance sheet and provide greater flexibility during this high-growth period.
Eden is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.
Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides.
To read Eden Research's recently released Interim Results click here
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.